Novo Nordisk: Is This 22% Drop a BUYING Opportunity or a Trap? скачать в хорошем качестве

Novo Nordisk: Is This 22% Drop a BUYING Opportunity or a Trap?

My App To Analyze Stocks : https://www.marg-in.com/join Follow me on X/Twitter : https://x.com/financeoptimale Connect on LinkedIn :   / guillaume-fournier-63a40a177   Novo Nordisk stock took a massive hit today, dropping nearly 22% in a single day! As a shareholder, I'm breaking down exactly why this happened and what it means for the future of one of the world's leading pharmaceutical companies. From a shocking guidance change for 2025, to the appointment of a new CEO, and the ongoing battle with compounded GLP-1s, there's a lot to unpack. Is this a temporary setback or a sign of deeper issues? And what am I doing with my investment after this significant loss? Join me as I discuss: The dramatic change in Novo Nordisk's sales and operating profit guidance. The impact of the new CEO, Mazhar Mike Durrani. The critical issue of compounded GLP-1s and Novo's strategy to combat them. A comparison with Eli Lilly and what it might reveal. My honest assessment of Novo Nordisk's financials and long-term viability. My personal investment journey with Novo and the lessons I'm learning from this dip. Whether you're a current Novo Nordisk investor, considering an investment, or just interested in the pharmaceutical market, this video will give you an in-depth look at the current situation. Disclaimer: I am not a financial advisor. This video is for informational and entertainment purposes only and should not be considered financial advice. Always conduct your own research and consult with a qualified financial professional before making any investment decisions. Investing in the stock market involves risk, and you may lose money. #NovoNordisk #StockMarket #Investment #GLP1 #Ozempic #Wegovy #StockAnalysis #Pharmaceuticals #InvestingLessons